Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dawn Broderick

Internal Medicine Olney, MD Medical Doctor

NPI 1801899489 CMS profile 36105

18111 Prince Philip Dr, Suite 201, Olney, MD 20832

Open in the dashboard

General payments

$3,854

214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dawn Broderick of Olney, MD is reported in the CMS Open Payments database as having received $3,854 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $372 19
2024 General $575 27
2023 General $508 24
2022 General $263 15
2021 General $956 56
2020 General $627 39
2019 General $554 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dawn Broderick
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dawn Broderick were reported at $372. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dawn Broderick Internal Medicine median Middle half National median
2019 $554 $159 $48–$570 $163
2020 $627 $119 $33–$402 $114
2021 $956 $135 $37–$521 $132
2022 $263 $141 $42–$496 $149
2023 $508 $149 $45–$519 $160
2024 $575 $154 $47–$537 $164
2025 $372 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $740 42 payments
  2. Pfizer Inc. $476 21 payments
  3. Novo Nordisk Inc $390 23 payments
  4. Lilly USA, LLC $352 17 payments
  5. AstraZeneca Pharmaceuticals LP $298 18 payments
  6. Merck Sharp & Dohme Corporation $262 17 payments
  7. Exact Sciences Corporation $229 11 payments
  8. Amgen Inc. $205 12 payments
  9. Allergan Inc. $173 13 payments
  10. Astellas Pharma US Inc $89 5 payments
  11. Other $641 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,848 213 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $374 22 payments
  2. Ozempic $320 19 payments
  3. ELIQUIS $283 13 payments
  4. RYBELSUS $254 14 payments
  5. FARXIGA $228 15 payments
  6. Cologuard Collection Kit $205 10 payments
  7. AIMOVIG $205 12 payments
  8. JARDIANCE $197 10 payments
  9. TRULICITY $187 9 payments
  10. SYNTHROID $186 10 payments
  11. Other $3,355 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

3,415

Median for Internal Medicine: 777

Drug cost

$480,079

Median for Internal Medicine: $73,373

Branded share of claims

24.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 92 $95,223
Ozempic Semaglutide Brand 40 $52,711
Rybelsus Semaglutide Brand 30 $47,950
Mounjaro Tirzepatide Brand 47 $46,814
Jardiance Empagliflozin Brand 22 $36,584
Januvia Sitagliptin Phosphate Brand 17 $27,357
Repatha Sureclick Evolocumab Brand 11 $17,478
Farxiga Dapagliflozin Propanediol Brand 14 $16,190
Myrbetriq Mirabegron Brand 18 $15,882
Praluent Pen Alirocumab Brand 12 $12,807

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $66
$66 — —
ELIQUIS
  • PFIZER INC. $38
$38 92 —
NURTEC ODT
  • PFIZER INC. $38
$38 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $36
$36 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record